» Articles » PMID: 27633807

Automated Processing of Dynamic Contrast-Enhanced MRI: Correlation of Advanced Pharmacokinetic Metrics with Tumor Grade in Pediatric Brain Tumors

Overview
Specialty Neurology
Date 2016 Sep 17
PMID 27633807
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Pharmacokinetic parameters from dynamic contrast-enhanced MR imaging have proved useful for differentiating brain tumor grades in adults. In this study, we retrospectively reviewed dynamic contrast-enhanced perfusion data from children with newly diagnosed brain tumors and analyzed the pharmacokinetic parameters correlating with tumor grade.

Materials And Methods: Dynamic contrast-enhanced MR imaging data from 38 patients were analyzed by using commercially available software. Subjects were categorized into 2 groups based on pathologic analyses consisting of low-grade (World Health Organization I and II) and high-grade (World Health Organization III and IV) tumors. Pharmacokinetic parameters were compared between the 2 groups by using linear regression models. For parameters that were statistically distinct between the 2 groups, sensitivity and specificity were also estimated.

Results: Eighteen tumors were classified as low-grade, and 20, as high-grade. Transfer constant from the blood plasma into the extracellular extravascular space (K), rate constant from extracellular extravascular space back into blood plasma (K), and extracellular extravascular volume fraction (V) were all significantly correlated with tumor grade; high-grade tumors showed higher K, higher K, and lower V. Although all 3 parameters had high specificity (range, 82%-100%), K had the highest specificity for both grades. Optimal sensitivity was achieved for V, with a combined sensitivity of 76% (compared with 71% for K and K).

Conclusions: Pharmacokinetic parameters derived from dynamic contrast-enhanced MR imaging can effectively discriminate low- and high-grade pediatric brain tumors.

Citing Articles

Differentiating Low-Grade from High-Grade Intracranial Ependymomas: Comparison of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted Imaging.

Arevalo-Perez J, Yllera-Contreras E, Peck K, Hatzoglou V, Yildirim O, Rosenblum M AJNR Am J Neuroradiol. 2024; 45(7):927-933.

PMID: 38782589 PMC: 11286012. DOI: 10.3174/ajnr.A8226.


Current state of pediatric neuro-oncology imaging, challenges and future directions.

Nabavizadeh A, Barkovich M, Mian A, NGo V, Kazerooni A, Villanueva-Meyer J Neoplasia. 2023; 37:100886.

PMID: 36774835 PMC: 9945752. DOI: 10.1016/j.neo.2023.100886.


Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas.

Goncalves F, Viaene A, Vossough A Front Neurol. 2021; 12:733323.

PMID: 34858308 PMC: 8631300. DOI: 10.3389/fneur.2021.733323.


Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.

Vajapeyam S, Brown D, Billups C, Patay Z, Vezina G, Shiroishi M AJNR Am J Neuroradiol. 2020; 41(4):718-724.

PMID: 32241771 PMC: 7144652. DOI: 10.3174/ajnr.A6499.


A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.

Baxter P, Su J, Onar-Thomas A, Billups C, Li X, Poussaint T Neuro Oncol. 2020; 22(6):875-885.

PMID: 32009149 PMC: 7283021. DOI: 10.1093/neuonc/noaa016.


References
1.
Pope W . Predictive imaging marker of bevacizumab efficacy: perfusion MRI. Neuro Oncol. 2015; 17(8):1046-7. PMC: 4490878. DOI: 10.1093/neuonc/nov067. View

2.
Larsson C, Kleppesto M, Grothe I, Vardal J, Bjornerud A . T1 in high-grade glioma and the influence of different measurement strategies on parameter estimations in DCE-MRI. J Magn Reson Imaging. 2014; 42(1):97-104. DOI: 10.1002/jmri.24772. View

3.
Mills S, Soh C, Rose C, Cheung S, Zhao S, Parker G . Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma.... AJNR Am J Neuroradiol. 2009; 31(3):549-53. PMC: 7963970. DOI: 10.3174/ajnr.A1844. View

4.
Harris R, Cloughesy T, Hardy A, Liau L, Pope W, Nghiemphu P . MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2015; 122(3):497-505. DOI: 10.1007/s11060-015-1755-8. View

5.
Pollack I . Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr. 2011; 8(2):135-48. DOI: 10.3171/2011.5.PEDS1178. View